| P50 | author | Hedvig Nordeng | Q21402733 |
| | Olav Spigset | Q64158961 |
| | Lars Jacob Stovner | Q29998759 |
| P2093 | author name string | Kateřina Nezvalová-Henriksen | |
| | Siri Amundsen | |
| P2860 | cites work | Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions | Q24568175 |
| | Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society | Q24633523 |
| | Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society | Q24633546 |
| | Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion | Q24635074 |
| | Migraine in women: the role of hormones and their impact on vascular diseases | Q26853088 |
| | Excretion of paracetamol in human breast milk | Q70870816 |
| | Atenolol and metoprolol. A comparison of their excretion into human breast milk | Q70944475 |
| | Metoclopramide and breast feeding: transfer into milk and the newborn | Q71166888 |
| | Distribution and excretion of sumatriptan in human milk | Q71675382 |
| | Course of migraine during pregnancy and postpartum: a prospective study | Q73185280 |
| | Perinatal indomethacin treatment and neonatal complications in preterm infants | Q73422204 |
| | Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study | Q73574165 |
| | The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age | Q73682087 |
| | Induction of CYP2D6 in pregnancy | Q73846474 |
| | Headache during pregnancy | Q73941883 |
| | Pregnancy outcome following first trimester exposure to sumatriptan | Q77114416 |
| | Functional reactivity of 5-HT receptors in human umbilical cord and maternal subcutaneous fat arteries after normotensive or pre-eclamptic pregnancy | Q79775491 |
| | Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study | Q80160560 |
| | Risk of preeclampsia in relation to maternal history of migraine headaches | Q81446558 |
| | Domperidone: QT prolongation in infants | Q83776863 |
| | Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes | Q84183136 |
| | Errata in "Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the norwegian mother and child cohort study" | Q84932338 |
| | Headache in pregnancy | Q87225177 |
| | ACE inhibitors, angiotensin II receptor blockers and pregnancy: fetal renal impairment | Q95480722 |
| | Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review | Q27023098 |
| | Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn | Q27026121 |
| | Anti-inflammatory pharmacotherapy during pregnancy | Q28167716 |
| | Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn | Q28176522 |
| | Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study | Q28199350 |
| | EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force | Q28256451 |
| | Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother | Q28258937 |
| | Renal follow up of premature infants with and without perinatal indomethacin exposure | Q28345307 |
| | Associations between acetaminophen use during pregnancy and ADHD symptoms measured at ages 7 and 11 years | Q28543188 |
| | Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study | Q30540714 |
| | Thrombocytopenic purpura in an infant after administration of acetylsalicylic acid to the wet-nurse | Q33475449 |
| | Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study | Q33515892 |
| | Migraine in pregnancy. | Q33733126 |
| | The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. | Q33863487 |
| | Anticonvulsant use during lactation | Q33956721 |
| | Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study | Q33971337 |
| | Epidemiology of headache in Europe | Q33995405 |
| | Analgesics and breast-feeding: safety considerations | Q33999232 |
| | Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism | Q34023712 |
| | Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain | Q34029017 |
| | Beta blockers and lactation: an update | Q34128025 |
| | Antidepressant use and risk for preeclampsia | Q34158083 |
| | Maternal treatment with opioid analgesics and risk for birth defects | Q34166412 |
| | Canadian Headache Society guideline for migraine prophylaxis. | Q34280265 |
| | Focal migraine and pregnancy | Q34290687 |
| | Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism | Q34340977 |
| | Canadian Headache Society Guideline: acute drug therapy for migraine headache | Q34365927 |
| | Metoclopramide in pregnancy and risk of major congenital malformations and fetal death | Q34377936 |
| | Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study | Q34380481 |
| | Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan | Q43586097 |
| | Nonsteroidal anti-inflammatory drugs in early pregnancy | Q43698756 |
| | Postpartum migraines: a long-term prospective study | Q43820152 |
| | Migraine prevalence, disease burden, and the need for preventive therapy | Q43983035 |
| | Pregnancy outcome following prescription for sumatriptan | Q44052356 |
| | Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations | Q44169560 |
| | OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report | Q44454503 |
| | In utero exposure to nonsteroidal anti-inflammatory drugs: neonatal renal failure | Q44675543 |
| | Triptan safety during pregnancy: a Norwegian population registry study | Q44696855 |
| | Infant rash caused by paracetamol in breast milk? | Q44754307 |
| | Neonate characteristics after maternal use of antidepressants in late pregnancy | Q44832133 |
| | Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. | Q46004711 |
| | Topiramate use in pregnancy and the birth prevalence of oral clefts | Q46101620 |
| | Delivery outcome after maternal use of drugs for migraine: a register study in Sweden | Q46226323 |
| | Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis | Q46344406 |
| | Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group | Q46355603 |
| | Association between topiramate and zonisamide use during pregnancy and low birth weight | Q47186799 |
| | Maternal ingestion of diclofenac leading to renal failure in newborns | Q47555661 |
| | Breast milk magnesium and calcium concentrations following magnesium sulfate treatment. | Q51860278 |
| | Breastfeeding and the Use of Human Milk | Q54152651 |
| | Migraine is a Risk Factor for Hypertensive Disorders in Pregnancy: A Prospective Cohort Study | Q59729401 |
| | Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders | Q34406553 |
| | Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. | Q34415797 |
| | Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study | Q34512958 |
| | Metoprolol excretion into breast milk | Q34518682 |
| | Major congenital malformations after first-trimester exposure to ACE inhibitors | Q34535854 |
| | Anti-emetics | Q35015214 |
| | Headache and migraine during pregnancy and puerperium: the MIGRA-study | Q35113489 |
| | Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study | Q35137516 |
| | Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. | Q35214960 |
| | Breastfeeding and migraine drugs | Q35250900 |
| | Trimester-specific blood pressure levels and hypertensive disorders among pregnant migraineurs | Q35552430 |
| | Migraine in special populations. Treatment strategies for children and adolescents, pregnant women, and the elderly | Q35750501 |
| | Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth | Q36102625 |
| | Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion | Q36188642 |
| | Brain damage in preterm newborns and maternal medication: the ELGAN Study | Q36205919 |
| | Use of topiramate in pregnancy and risk of oral clefts | Q36356810 |
| | Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis | Q36459968 |
| | Triptans in pregnancy | Q36817033 |
| | Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study | Q36930421 |
| | Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study | Q37136848 |
| | Botulinum toxin type A in pregnancy | Q37308583 |
| | Guidelines for maternal codeine use during breastfeeding. | Q37419914 |
| | Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies | Q37650066 |
| | Migraine therapy during pregnancy and lactation | Q37775960 |
| | Contemporary management of migrainous disorders in pregnancy | Q37798696 |
| | Headaches during pregnancy | Q37861566 |
| | Migraine in pregnancy and lactation | Q38194053 |
| | Fertility and infertility in rheumatoid arthritis | Q38198947 |
| | School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo | Q38423595 |
| | Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs | Q39392149 |
| | Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects | Q40537662 |
| | Propranolol in human plasma and breast milk | Q41474294 |
| | Neonatal complications after the administration of indomethacin for preterm labor | Q42286520 |
| | Is maternal opioid use hazardous to breast-fed infants? | Q43063862 |
| | First trimester diclofenac exposure and pregnancy outcome | Q43075777 |
| | Danish group reanalyses miscarriage in NSAID users | Q43123886 |
| | Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study | Q43173466 |
| | Nonsteroidal antiinflammatory drug use among women and the risk of birth defects | Q43572859 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breastfeeding | Q174876 |
| | migraine | Q133823 |
| P304 | page(s) | 209-219 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Nature Reviews Neurology | Q2079285 |
| P1476 | title | Pharmacological treatment of migraine during pregnancy and breastfeeding | |
| P478 | volume | 11 | |